Merck And Vertex Poised For Growth In Singapore's HCV Market As Medical Tourism Booms
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Novel hepatitis C treatments from Merck and Vertex are expected to fare well in Singapore - with the proper marketing campaigns - due in part to increased medical tourism from neighboring Southeast Asian countries